Home› Library› Protocol› Tesamorelin

ProtocolTesamorelinMay 18, 2026

Tesamorelin reconstitution protocol

Reconstitution and storage parameters for tesamorelin, a stabilized GHRH(1-44) analog. Reference values from published handling literature.

CATALOG UPDATE

Tesamorelin is moving to our prescription channel. Same molecular standards via a partner 503B compounding pharmacy. Join the waitlist for first access.

Join waitlist →

RECONSTITUTION & RESEARCH PROTOCOLS

Phase 3 RCT evidence

Research protocol intensities, summarized from published literature. The math is computed for the vial size you pick. Not a dosing recommendation.

FDA-approved (Egrifta) for HIV-associated lipodystrophy. NEJM 2007 + AIDS 2011 trial publications.

RESEARCH MODE
Final concentration
—

Reference research protocols from published peer-reviewed studies. Each card cites its source. This calculator is not a dosing recommendation. For research use only. Selection of any specific protocol is the responsibility of the qualified investigator under appropriate institutional oversight.

This protocol describes the reconstitution and storage of lyophilized tesamorelin in standard research workflows. Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) — it's the only GHRH analog approved for clinical use, originally for HIV-associated lipodystrophy research. Values below are derived from published handling literature; experimental design parameters are the responsibility of the qualified investigator.

At a glance

Parameter Value
Recommended diluent Bacteriostatic Water (USP, 0.9% benzyl alcohol)
Recommended volume (10 mg vial) 2.0 mL
Final concentration 5 mg/mL
Stability — lyophilized ≥24 months at -20 °C, light-protected, sealed
Stability — reconstituted 14 days at 2–8 °C in original vial
Freeze-thaw Avoid on reconstituted solution. Aliquot for extended storage.

Procedure

  1. Equilibrate the vial to room temperature.
  2. Sterile prep: wipe stopper with isopropyl, allow to dry. Use sterile syringe and 21G or larger needle.
  3. Inject diluent slowly along the inner glass wall. Tesamorelin is moderately sensitive to mechanical stress during reconstitution.
  4. Swirl gently. Do not shake. Cake dissolves within 30–60 seconds.
  5. Verify: solution should be clear and colorless.

Compound notes

Tesamorelin is a 44-amino-acid analog of native GHRH, with a trans-3-hexenoyl modification at the N-terminus that increases resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. This modification approximately doubles the in-vivo half-life compared to native GHRH while preserving full agonist activity at the GHRH receptor. The molecule still has a relatively short plasma half-life (~26 minutes) compared to the long-acting CJC-1295, so research protocols typically use daily administration in rodent models.

The reconstituted form is somewhat less stable than tirzepatide or BPC-157 in solution — plan for 14 days at refrigerated storage rather than the standard 30. Aliquot if you need a longer experimental window.

Storage

Reconstituted tesamorelin is stable for approximately 14 days at 2–8 °C. For longer storage, aliquot into sterile single-use tubes and freeze at -20 °C or colder. Lyophilized stability is ≥24 months at -20 °C light-protected.

Notes

This protocol describes reconstitution parameters from published peptide-handling literature. It is not a recommendation for any specific study design. For research use only. Not for human consumption.

References

  1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM 2007;357:2359–2370. PMID: 18057338
  2. Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS 2011;25:1281–1288. PMID: 21516029

Was this helpful?

Tell us what we got wrong or what would have helped — optional. We read every reply.

Thanks — we got it.
Have a question we didn't answer?
We reply to every research inquiry.
Email Merit →